Projects funded by the NCN
Inhibition of p21-Activated Kinase (PAK) as a new molecular target in the treatment of chronic myeloid leukemia (CML)
2013/11/B/NZ7/02248
Keywords:
chronic myeloid leukemia (CML) tyrosine kinase inhibitors (TKI) PAK inhibitor apoptosis ROS
Descriptors:
- NZ7_14: Pharmacy, pharmacotherapy, pharmacology
Panel:
NZ7 - Diagnostic tools, therapies and public health: public health, epidemiology, environmental health risks and occupational medicine, medical ethics, drug discovery and therapies, pharmacology
Host institution :
Narodowy Instytut Leków
woj. mazowieckie
Principal investigator (from the host institution):
Number of co-investigators in the project: 5
Call: OPUS 6 - announced on 2013-09-16
Amount awarded: 638 828 PLN
Project start date (Y-m-d): 2014-09-10
Project end date (Y-m-d): 2019-09-09
Project duration:: 60 months (the same as in the proposal)
Project status: Project settled